GlassScriptPhysician profile
Donna Curry
NPI 1902114275
$901.55
in general payments reported to CMS, 2019-2025
16 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $98.09 · 2024: $447 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $170.04 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $120.96 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $120.72 | 2024 | Airsupra |
| Abbvie INC. | $108.03 | 2024-2025 | |
| Glaxosmithkline, LLC. | $58.80 | 2023 | Arexvy |
| Jazz Pharmaceuticals INC. | $56.26 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $49.90 | 2024 | Rexulti |
| Alkermes, INC. | $39.31 | 2024 | Lybalvi, Vivitrol |
| Pfizer INC. | $39.29 | 2023 | |
| Sumitomo Pharma America, INC. | $28.99 | 2024 | Gemtesa |
| Nevro Corp. | $24.93 | 2024 | Senza |
| Ultragenyx Pharmaceutical INC. | $21.45 | 2024 | Crysvita |
| Corcept Therapeutics | $20.04 | 2024 | Korlym |
| Vanda Pharmaceuticals INC. | $19.95 | 2024 | Fanapt |
| Novartis Pharmaceuticals Corporation | $18.79 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4.09 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.